Glen Harbor Capital Management’s AMAG Pharmaceuticals AMAG Stock Holding History

Glen Harbor Capital Management’s Portfolio AMAG Stock Details AMAG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$186K	Buy	16,116 +3,706	+30%	+$39K	﹤0.01%	1040
2019 Q2	$124K	Buy	12,410 +3,026	+32%	+$32.6K	﹤0.01%	1135
2019 Q1	$121K	Hold	9,384	–	–	﹤0.01%	1114
2018 Q4	$143K	Hold	9,384	–	–	﹤0.01%	1039
2018 Q3	$188K	Hold	9,384	–	–	﹤0.01%	1078
2018 Q2	$183K	Hold	9,384	–	–	﹤0.01%	999
2018 Q1	$189K	Buy	9,384 +1,224	+15%	+$20.7K	﹤0.01%	989
2017 Q4	$108K	Buy	8,160 +1,836	+29%	+$27.7K	﹤0.01%	1140
2017 Q3	$117K	Buy	6,324 +1,734	+38%	+$32.3K	﹤0.01%	1082
2017 Q2	$84K	Buy	4,590 +2,380	+108%	+$47.2K	﹤0.01%	1124
2017 Q1	$50K	Buy	2,210 +102	+5%	+$2.44K	﹤0.01%	1126
2016 Q4	$73K	Buy	+2,108	New	+$63K	﹤0.01%	1001

Other funds holding AMAG

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Glen Harbor Capital Management's AMAG Position: Q3 2019 in Review

Glen Harbor Capital Management increased its AMAG Pharmaceuticals (AMAG) stake by 30% in Q3 2019, buying an estimated $39K and bringing the position to 16,116 shares worth $186K. The position accounts for ﹤0.01% of the portfolio, ranked #1040.

Glen Harbor Capital Management first reported a position in AMAG in Q4 2016 and has held it in 12 quarters since. The position peaked at $189K in Q1 2018. 156 funds tracked by Wall St. Rank hold AMAG as of Q3 2019.

Glen Harbor Capital Management held 16,116 shares of AMAG Pharmaceuticals worth $186K as of Q3 2019.
Glen Harbor Capital Management bought 3,706 AMAG Pharmaceuticals shares in Q3 2019, an estimated $39K.
AMAG Pharmaceuticals made up ﹤0.01% of Glen Harbor Capital Management's portfolio in Q3 2019, its #1040 holding.
Glen Harbor Capital Management first reported a position in AMAG Pharmaceuticals in Q4 2016 and has held it in 12 quarters since.
Glen Harbor Capital Management's AMAG Pharmaceuticals position peaked at $189K in Q1 2018.
156 funds tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q3 2019.

Based on Glen Harbor Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.